

1 **Objective:** The diagnosis of vertigo is challenging, particularly as patients usually present whilst
2 asymptomatic. We have developed an ambulatory medical device that allows vestibular telemetry
3 to record eye movements over a 30-day period to aid the diagnosis of vertigo. We have undertaken
4 proof-of-concept work to identify unique properties of nystagmus that could be used to differentiate
5 between three of the most common causes of vertigo: Ménière's Disease, vestibular migraine, and
6 Benign Paroxysmal Positional Vertigo.

7 **Patients:** We analyse the nystagmus from patients with a diagnosis of Ménière's Disease, vestibular
8 migraine, and Benign Paroxysmal Positional Vertigo.

9 **Intervention(s):** Our vestibular telemetry system includes a wearable, ambulatory monitor which
10 continuously records horizontal and vertical eye-movements, as well as 3-axis movements of the
11 head.

12 **Main Outcome Measure(s):** Horizontal and vertical eye-movement data, and 3-axis head positioning
13 data.

14 **Results:** Sixteen participants were enrolled onto the study and three reported experiencing rotatory
15 vertigo during their thirty-day trial, confirmed by the presence of nystagmus in their eye-movement
16 traces. Vestibular telemetry revealed distinct differences between the nystagmus produced during
17 an acute Ménière's attack, and attacks of vestibular migraine and Benign Paroxysmal Positional
18 Vertigo. Attack frequency, nystagmus duration, whether the nystagmus onset was motion provoked,
19 nystagmus direction, slow phase velocity and slow phase duration were found to be discriminatory
20 features that could be exploited to allow an automated diagnosis to be made.

21 **Conclusions:** The data provided by vestibular telemetry can be used to differentiate between
22 different inner-ear causes of dizziness.

23
24
25
26
27
28
29
30
31
32
33
34

35 **Introduction**

36

37 Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo are three of the
38 most common causes of vertigo.¹ Ménière's disease and vestibular migraine are chronic conditions
39 affecting the inner ear that can result in repeated and prolonged episodes of vertigo, while Benign
40 Paroxysmal Positional Vertigo is characterised by short and frequent periods of motion-provoked
41 vertigo.²

42

43 The diagnosis of Ménière's disease and vestibular migraine is contentious as there are few definitive
44 and objective tests, and there is a significant overlap in the symptoms that patients report.³ Tests
45 that are currently available are usually performed while patients are asymptomatic. Clinicians rely on
46 the self-reporting of vertigo by patients, however an individual's interpretation of their dizziness is
47 highly subjective and the language used by patients is often ambiguous.⁴ Furthermore, patients can
48 wake to find themselves experiencing a vertigo attack, making it impossible for them to provide an
49 accurate account of attack onset.⁵ While relatively straightforward to diagnose Benign Paroxysmal
50 Positional Vertigo using the Dix-Hallpike diagnostic manoeuvre, some patients can wait several years
51 before Benign Paroxysmal Positional Vertigo is suspected by their clinician. Therefore, patients
52 suffering from Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo can
53 face extended periods of uncertainty with debilitating symptoms prior to receiving a correct
54 diagnosis and access to treatment.⁶

55

56 Recent advances in the field of vestibular telemetry have allowed the continuous ambulatory
57 assessment of individuals with dizziness, vertigo and balance disturbance.⁷⁻⁹ The Continuous
58 Ambulatory Vestibular Assessment system includes a piece of wearable technology, plus the
59 algorithms necessary to analyse the data it records. Detailed information regarding the system is
60 available elsewhere,⁸ but in essence, it allows the near-continuous monitoring of eye and head
61 movements of individuals experiencing dizziness, for up to thirty days at a time. Parallels can be
62 drawn between this device and the 24-hour ECG tape that is used to identify cardiac arrhythmias.¹⁰
63 To suit the extended duration of wear, the device has been designed to be lightweight, ergonomic,
64 and easy for patients to maintain. The device records the corneo-retinal potential generated by the
65 eyes, in a similar way to the electronystagmography (ENG) technology used in clinical settings to
66 record eye movements during balance testing.¹¹ In recent years, video technology has largely
67 superseded ENG, but video is not suitable for an ambulatory monitor, as patients typically shut their

68 eyes during dizziness, video goggles are cumbersome to apply and technically inefficient, and there
69 are privacy concerns surrounding 24-hour video capture.

70

71 We have recently completed a healthy volunteer trial in which seventeen healthy participants wore
72 our device for up to thirty days.⁷ The data gathered was used to evaluate the diagnostic accuracy,
73 reliability, acceptability and safety of the device. Following this work, we are currently undertaking a
74 clinical investigation to evaluate the system's capability to identify periods of nystagmus
75 experienced by patients with Ménière's disease, vestibular migraine and Benign Paroxysmal
76 Positional Vertigo. Using data from participants enrolled onto this trial, we have undertaken proof of
77 concept work with the objective of identifying features of nystagmus that could be used to
78 differentiate our three conditions of interest. In this article, which is a step towards our future aim of
79 developing this system to provide an automated diagnosis for patients with vertigo, we present the
80 results of this proof of concept work.

81

82 **Materials and Methods**

83

84 The data analysed here is from participants enrolled onto a clinical trial to investigate the diagnostic
85 accuracy of the Continuous Ambulatory Vestibular Assessment (CAVA[®]) device. This trial has a
86 recruitment target of thirty-five participants, and sixteen participants have been enrolled onto the
87 study to date. This study forms part of a larger body of work funded by the UK Medical Research
88 Council to develop an advanced prototype medical system for detecting vertigo, and was reviewed
89 and approved by the London-Dulwich Research Ethics Committee (IRAS Number: 261099).

90

91 The device (Figure 1) records the corneo-retinal potential produced by the eyes, simultaneously
92 capturing horizontal and vertical eye movements. Five press stud ECG electrodes are contained
93 within single-use electrode mounts that connect to a reusable, electronic earpiece. Two electrodes
94 near the temples capture horizontal eye movements, two above the left eye record vertical
95 movements, and an electrode positioned under the right ear provides a reference voltage. Each
96 channel of eye movement is sampled at 42.67 Hz. The device also records head motions in three-
97 axes, sampled at a rate of 20 Hz.

98

99 Participants in the trial were expected to wear the device for thirty consecutive days, for up to 23
100 hours a day. An hour each day was allocated for washing and to replace the device's electrode pads.
101 The participants whose data are presented here were recruited as part of the initial unblinded

102 "training" phase of the investigation, in order to provide data to assist with the development of our
103 computer algorithms. In the event of experiencing an attack of rotatory vertigo, participants were
104 instructed to press an event marker button on the device and to keep a written record of the attack
105 start time and duration. This data was used to assist the research team with locating the associated
106 nystagmus data within the long-term data.

107

108 Based on preliminary work,⁹ together with our understanding of the distinctive characteristics of
109 nystagmus produced by Ménière's disease, vestibular migraine and Benign Paroxysmal Positional
110 Vertigo, we extracted a range of parameters from the nystagmus data to quantify the differences
111 between our three target conditions. These parameters were determined before we initiated the
112 study and included candidate parameters of potentially high discriminatory value – see table 1.
113 Nystagmus was identified from the data using our semi-automated nystagmus analysis software,
114 which identifies candidate nystagmus beats and presents them for manual confirmation or
115 rejection.⁸ The software automatically quantifies the nystagmus direction, slow phase velocity and
116 slow phase direction and the remaining parameters (i.e. attack frequency, nystagmus duration and
117 whether onset was motion-provoked) are determined through a combination of manual
118 interpretation of the software output and data from the participants' trial diaries.

119

120 **Results**

121

122 Upon returning their devices after thirty days, three of the sixteen participants enrolled reported
123 experiencing attacks of rotary vertigo whilst wearing the device. The remaining thirteen participants
124 either reported experiencing non-specific symptoms of imbalance (for which nystagmus was not
125 present), or they did not experience vertigo during the trial. We quantified the characteristics of the
126 nystagmus from the three participants who reported rotatory vertigo to determine whether there
127 were any identifiable differences between the three examples (see table 2). All features examined
128 provided a degree of discriminatory power, with the only overlap being an absence of motion-
129 provoked vertigo for Ménière's disease and vestibular migraine, and the frequency of attacks for
130 these conditions. There were differences between all three conditions in terms of nystagmus
131 duration, nystagmus direction, the temporal characteristics of nystagmus direction, and the velocity
132 and duration of the nystagmus slow phases.

133

134 Participant one was a 53-year-old lady with a fifteen-year history of left sided unilateral Ménière's
135 disease. Please refer to our previous work for a detailed timeline of this participant's vertigo and

136 associated nystagmus.⁹ For reference, the participant had recently reported discrete episodes of
137 rotatory vertigo lasting for several hours. During the trial, the participant reported a single episode
138 of vertigo lasting for approximately two hours (see figure 2). The attack comprised eight periods of
139 nystagmus, each lasting between approximately 21 and 460 seconds. Over the course of the attack,
140 the nystagmus direction alternated from right-beating to left-beating, back to right-beating, and
141 finally to left-beating.

142
143 Participant two was a 36-year-old lady with a 22-year history of vestibular migraine. She reported
144 distinct episodes of rotatory vertigo lasting for up to an hour. During the trial, she reported a single
145 attack of rotatory vertigo lasting for approximately an hour (see figure 3). This nystagmus trace is
146 markedly different to that of participant one, as the slow phase durations are longer, the slow phase
147 velocities are lower, and the nystagmus is more intermittent. The longer-term characteristics of the
148 vertigo were also different, as the nystagmus direction did not change throughout the attack, and
149 the attack was much shorter overall.

150
151 Participant three was a 56-year-old lady with a three-year history of positional vertigo. She reported
152 periods of rotatory vertigo lasting for a few seconds at a time, which were initiated by moving her
153 head into certain positions. During the trial, she reported sixteen attacks of rotatory vertigo, lasting
154 for around 10 seconds at a time. With the participant's consent, she also underwent diagnostic Dix-
155 Hallpike manoeuvres at follow-up appointments during the trial, while also wearing the device (see
156 figure 4). The concurrent accelerometer data showed that nystagmus onset was preceded by a
157 significant movement of the head, occurring approximately 12 minutes and 8 seconds after device
158 activation. This movement is consistent with a right-sided Dix-Hallpike manoeuvre, and corresponds
159 to the participant moving from an upright to a supine position, with the affected ear facing
160 downwards. The horizontal eye-movement trace for this participant is very different to the traces
161 from patients one and two, as it shows no evidence of jerk nystagmus. By contrast, the vertical trace
162 was relatively stationary until the onset of nystagmus, which occurred at about 12 minutes 20
163 seconds after device activation. At that time, an oscillatory eye-movement is visible. Interestingly,
164 the nystagmus subsided briefly and then resumed more intensely about 7 seconds later. As the
165 second wave of the nystagmus progressed, the signal first increased and then decreased in
166 amplitude, before finally ending. The total duration of the nystagmus was about 20 seconds.

168 Discussion

169

170 Strengths of the study

171

172 In this article we have provided valuable proof-of-concept data showing that three of the most
173 common inner-ear causes of vertigo can be discriminated based on a range of quantifiable
174 characteristics of nystagmus. Furthermore, data from our system is capable of providing this
175 discriminative information. The scope and detail of this data was only possible due to the long-term
176 duration of data capture and because patients wore the device during their normal daily activities,
177 rather than during a limited assessment in a clinical setting. This provides reassurance that further
178 insights could be obtained from studying a larger cohort of patients and confirms proof-of-concept
179 that an automated algorithmic approach to diagnosing the cause of dizziness is possible.

180

181 Synopsis of key findings

182

183 All of the nystagmus parameters we explored provided a high level of discrimination between the
184 three diseases under investigation. Two parameters could be used to discriminate Benign
185 Paroxysmal Positional Vertigo from Ménière's disease and vestibular migraine (Attack frequency and
186 Motion-provoked onset). Four parameters provided sufficient information to differentiate all three
187 conditions (nystagmus duration, nystagmus direction, slow phase velocity and slow phase duration).
188 When presented with the findings from the device, participants expressed agreement with the
189 results, which provided a more precise account than the trial diaries kept by the participants.

190

191 Clinical applicability of the study

192

193 We have confirmed that there are characteristics of nystagmus which differ between three of the
194 most common inner-ear causes of dizziness. Just as we have previously applied machine-learning to
195 detect pathological nystagmus,¹² and similar techniques have been applied to other areas of
196 otolaryngology, such as oncology and neurotology,¹³ the features identified here could be used to
197 develop a system to automatically diagnose the cause of a patient's vertigo. The amount of data
198 captured by our device during thirty-days makes manual analysis by a clinician infeasible. An
199 automated approach to diagnosis, such as that proposed here, could be used to efficiently identify
200 candidate nystagmus signals without the need for time-consuming manual inspection of all available
201 data. As the long-term parameters of the vestibular disorders presented here have been hitherto
202 unavailable, it is also likely that future data from the device could be used to support or improve
203 existing diagnostic guidelines and to shed further insight into other conditions resulting in vertigo.

204

205 The COVID-19 pandemic has led to unprecedented financial pressures on world economies and has
206 motivated the need to find financial savings across all areas of public health services. In 2013, the
207 estimated annual cost of patients attending an emergency department due to dizziness or vertigo
208 was greater than 4 billion US\$.¹⁴ Routine use of a system such as ours would reduce the number of
209 hospital visits and the number of diagnostic tests required before patients receive treatment,
210 reducing the costs incurred to diagnose patients with dizziness. A further benefit of telehealth
211 techniques such as ours is in helping to reduce the transmission of viruses, such as COVID-19, which
212 is likely to remain a pertinent issue in medicine for years to come.

213

214 The potential to automatically differentiate between Ménière's disease and vestibular migraine is a
215 key advantage of our system, as these conditions have a significant degree of overlap in their
216 presentation. There is benefit in correctly diagnosing these conditions to provide access to
217 appropriate treatments and to avoid unnecessary interventions, as their treatments vary in terms of
218 invasiveness and risk. Patients with Ménière's disease may be treated with invasive injections into
219 the middle ear which, as well as being unpleasant for patients, carries risks of infection, damage to
220 the tympanic membrane and in rare cases, hearing loss. Although a range of drugs are available for
221 patients with vestibular migraine, these drugs are not without risk and the process of finding the
222 right drug can be time consuming. Delaying the correct treatment also prolongs the suffering of
223 patients.

224

225 It might be argued that using our system to diagnose Benign Paroxysmal Positional Vertigo is
226 unnecessary, as patients are often able to identify the link between head movements and the onset
227 of dizziness, and it can be easily identified in clinical settings using the Dix-Hallpike manoeuvre. But
228 not all patients will make this association and symptoms of dizziness upon head movement could
229 indicate space and motion discomfort, rather than Benign Paroxysmal Positional Vertigo. The Dix-
230 Hallpike test itself does not provide perfect diagnostic sensitivity.¹⁵ We have encountered patients
231 who, following a positive Dix-Hallpike test, produced a negative result 24-hours later, and a positive
232 result after that. Therefore, considering only a single Dix-Hallpike test in isolation could lead to an
233 incorrect diagnosis being made. While preceding head movements are one discriminatory
234 characteristic of positional vertigo, nystagmus duration provides a further level of discrimination.
235 The atypical nystagmus signal presented here is also a useful discriminator. In summary, there is
236 potential value in using our system to diagnose patients reporting persistent and unexplained
237 vertigo, for which Benign Paroxysmal Positional Vertigo could be one possible cause.

238

239 Patients enrolled onto our study expressed an increased willingness to explore the boundaries of
240 their dizziness whilst wearing the device. For example, one participant with suspected Ménière's
241 disease had reduced their salt, caffeine and alcohol intake, following information they'd obtained
242 through their own research. During the patient's trial, they cautiously restarted eating these items
243 and found them to have no impact on their dizziness symptoms. Such stories are common among
244 patients with Ménière's disease or vestibular migraine, as patients seek to identify triggers for their
245 vertigo. It is often easy for patients to form faulty generalisations by confusing coincidence with
246 causality, leading to lifestyle limiting changes that have little or no effect on their symptoms. Our
247 system gives patients the confidence to retest their assumptions and to remove such self-imposed
248 restrictions on daily life.

249

250 Comparisons with other studies

251

252 There have been a handful of previous attempts to develop devices similar to ours, but all have had
253 a number of limitations compared to the approach adopted here. Previous approaches have been
254 limited in terms of the continuous duration of data capture, either due to data storage or battery
255 requirements.¹⁶⁻¹⁸ Most approaches require patients to apply and activate a device at the onset of
256 dizziness,^{17,18} which is challenging for patients experiencing an attack and this approach would not
257 record pre-attack data such as the prodrome we have previously identified in a patient with
258 Ménière's disease.⁹ Despite their limitations, these previous attempts to develop a portable vertigo
259 monitor do provide confirmation of the clinical need for and interest in a device such as this. More
260 importantly, one of these studies was able to capture nystagmus from patients with Ménière's
261 disease and vestibular migraine, and their results support our finding that the slow phase velocity is
262 a discriminative feature of Ménière's disease and vestibular migraine.¹⁸ Studies have also observed
263 the direction-changing characteristics of Ménière's disease, whereby nystagmus direction alternates
264 between left and right-beating during an attack, with more time spent beating towards the affected
265 ear.¹⁸⁻²⁰ Our study has confirmed this finding and found it to be a useful factor for differentiating
266 Ménière's disease from vestibular migraine.

267

268 Limitations of the study and further work

269

270 One limitation of this study is the low incidence of symptomatic patients recruited, with three out of
271 sixteen patients experiencing rotatory vertigo during their thirty-day trial. To address this, we intend

272 to confirm our findings by conducting a much larger investigation involving several hundreds of
273 patients. Beyond that, we will determine if vestibular telemetry could be used to distinguish a range
274 of other conditions resulting in dizziness, such as acoustic neuroma, vestibular neuritis and stroke.
275 Another limitation is that here we have used a semi-automatic analysis of the patient data to
276 manually determine the discriminative features of our target conditions. In future, we intend to
277 develop computer algorithms to fully automatically diagnose patients from the data provided by the
278 device. There are a range of machine learning techniques which could be applied to this task,
279 including traditional approaches and also more contemporary methods such as deep neural
280 networks. We suggest that there are broadly two approaches to address this problem: firstly, the
281 eye-movement signals themselves may be sufficiently informative to be discriminated directly.
282 Secondly, a multi-stage approach might be better, whereby algorithms start by detecting the
283 presence of nystagmus, and then the diagnosis is based upon higher-level features such as those
284 described here. We hope that by sharing our findings with the scientific and medical communities,
285 we may inspire others to focus their attentions on the emerging field of vestibular telemetry.

287 Declaration of Interest Statement

288 There are no relevant competing interests to declare.
289
290

291 Data Availability Statement

292
293 The data presented here is available upon reasonable request.
294

295 References

- 296 1. Kim H-J, Lee J-O, Choi J-Y, Kim J-S. Etiologic distribution of dizziness and vertigo in a referral-
297 based dizziness clinic in South Korea. *Journal of Neurology*. 2020;267(8):2252-2259.
298 doi:10.1007/s00415-020-09831-2
- 299 2. Lempert T, Neuhauser H. Epidemiology of vertigo, migraine and vestibular migraine. *Journal of*
300 *Neurology*. 2009;256(3):333-338. doi:10.1007/s00415-009-0149-2
- 301 3. Tabet P, Saliba I. Meniere's Disease and Vestibular Migraine: Updates and Review of the
302 Literature. *J Clin Med Res*. 2017;9(9):733-744. doi:10.14740/jocmr3126w
- 303 4. Newman-Toker DE, Cannon LM, Stofferahn ME, Rothman RE, Hsieh Y-H, Zee DS. Imprecision in
304 Patient Reports of Dizziness Symptom Quality: A Cross-sectional Study Conducted in an Acute
305 Care Setting. *Mayo Clinic Proceedings*. 2007;82(11):1329-1340. doi:10.4065/82.11.1329
- 306 5. Mumford CJ. Post-traumatic benign paroxysmal positional vertigo. *Pract Neurol*. 2019;19(4):354.
307 doi:10.1136/practneurol-2018-002117

- 308 6. Chawla N, Olshaker JS. Diagnosis and Management of Dizziness and Vertigo. *Medical Clinics of*
309 *North America*. 2006;90(2):291-304. doi:10.1016/j.mcna.2005.11.003
- 310 7. Phillips JS, Newman JL, Cox SJ. An investigation into the diagnostic accuracy, reliability,
311 acceptability and safety of a novel device for Continuous Ambulatory Vestibular Assessment
312 (CAVA). *Scientific Reports*. 2019;9(1):10452. doi:10.1038/s41598-019-46970-7
- 313 8. Newman JL, Phillips JS, Cox SJ, FitzGerald J, Bath A. Automatic nystagmus detection and
314 quantification in long-term continuous eye-movement data. *Computers in Biology and Medicine*.
315 Published online 2019:103448. doi:https://doi.org/10.1016/j.combiomed.2019.103448
- 316 9. Phillips JS, Newman JL, Cox SJ, FitzGerald J. Nystagmus during an acute Ménière's attack: from
317 prodrome to recovery. *null*. Published online July 31, 2020:1-5.
318 doi:10.1080/14992027.2020.1799252
- 319 10. Bansal A, Joshi R. Portable out-of-hospital electrocardiography: A review of current
320 technologies. *Journal of Arrhythmia*. 2018;34(2):129-138. doi:10.1002/joa3.12035
- 321 11. McCaslin DL. In: *Electronystagmography and Videonystagmography (ENG/VNG)*. Plural
322 Publishing; 2013:74-77.
- 323 12. J. L. Newman, J. Phillips, S. Cox. 1D Convolutional Neural Networks for Detecting Nystagmus.
324 *IEEE Journal of Biomedical and Health Informatics*. Published online 2020:1-1.
325 doi:10.1109/JBHI.2020.3025381
- 326 13. Crowson MG, Ranisau J, Eskander A, et al. A contemporary review of machine learning in
327 otolaryngology-head and neck surgery. *Laryngoscope*. 2020;130(1):45-51.
328 doi:10.1002/lary.27850
- 329 14. Saber Tehrani AS, Coughlan D, Hsieh YH, et al. Rising annual costs of dizziness presentations to
330 U.S. emergency departments. *Acad Emerg Med*. 2013;20(7):689-696. doi:10.1111/acem.12168
- 331 15. Halker RB, Barrs DM, Wellik KE, Wingerchuk DM, Demaerschalk BM. Establishing a diagnosis of
332 benign paroxysmal positional vertigo through the dix-hallpike and side-lying maneuvers: a
333 critically appraised topic. *Neurologist*. 2008;14(3):201-204. doi:10.1097/NRL.0b013e31816f2820
- 334 16. Rauch S, Wall C, Tuthill E, Roberts T. *Ambulatory Monitors*. US Patent Application Publication
335 No.: US 2007/0010748A1; 2007.
- 336 17. Wolf SR, Christ P, Haid CT. "Telemetric" Electronystagmography: A New Method for Examination
337 of Nystagmus Outside the Clinic. *null*. 1991;111(sup481):374-381.
338 doi:10.3109/00016489109131426
- 339 18. Young AS, Lechner C, Bradshaw AP, et al. Capturing acute vertigo. *Neurology*.
340 2019;92(24):e2743. doi:10.1212/WNL.0000000000007644
- 341 19. Bance M, Mai M, Tomlinson D, Rutka J. The changing direction of nystagmus in acute Meniere's
342 disease: Pathophysiological implications. *The Laryngoscope*. 1991;101(2):197-201.
343 doi:10.1288/00005537-199102000-00017
- 344 20. Watanabe T. Nystagmus during an acute attack of Meniere's disease. *ENG Report*. Published
345 online 1996:1-3.

346

347

348

349 **Figure 1:** The device includes a reusable logging module and two electrode mounts, containing five
350 ECG electrodes. Patients can press the event marker button on the device to log the date and time
351 of an activity of interest (e.g. an episode of dizziness). Holding the button for four seconds initiates
352 the device's status check feature, with an LED then providing a visual warning of a low battery, a
353 poor electrode connection, or normal device operation.

354

355 **Figure 2:** A 30-second horizontal eye-movement trace from an acute attack of Ménière's Disease, as
356 captured by the device. A computer analysis was applied to these traces to automatically detect the
357 fast (red) and slow (green) phases of the nystagmus, and the results were manually confirmed by a
358 scientist. The analysis confirmed the presence of nystagmus, which alternated in direction
359 throughout the attack and which is left-beating in this extract.

360

361 **Figure 3:** A 30-second horizontal eye-movement trace from an attack of vestibular migraine, as
362 captured by the device. A computer analysis was applied to these traces to automatically detect the
363 fast (red) and slow (green) phases of the nystagmus. The analysis confirmed the presence of
364 nystagmus, which is right-beating for the entire duration of this attack.

365

366 **Figure 4:** 30-second (a) horizontal and (b) vertical eye-movement traces and (c) concurrent
367 accelerometer trace from an attack of Benign Paroxysmal Positional Vertigo, as captured by the
368 device. The three vertical black lines in each trace show activations of the device's event marker
369 prior to the manoeuvre, approximately 5 seconds after the onset of nystagmus, and after the
370 nystagmus had subsided. The eye-movement signals were analysed by manual inspection, as the
371 traces are different to the "jerk" nystagmus shown in figures 2 and 3. The signals show an oscillatory
372 eye movement, occurring predominantly in the vertical channel.

373